Metabolism drugs refer to medications that regulate, repair, or replace metabolic processes in the body. These include drugs for diabetes, thyroid diseases, obesity, and other metabolic disorders. The major types of metabolism drugs available in the market are diabetes drugs, anti-obesity drugs, and thyroid hormones. Diabetes drugs are designed to control blood sugar levels by stimulating insulin production or enhancing the effects of insulin in the body. Anti-obesity drugs aid in weight loss by decreasing appetite or blocking fat absorption. Thyroid hormones are used for treating hyperthyroidism and hypothyroidism by regulating the rate of metabolism. These drugs play a crucial role in improving patient health and quality of life for those suffering from metabolic disorders.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The rising prevalence of metabolic disorders globally presents a major market opportunity for metabolism drugs. According to WHO estimates, the prevalence of diabetes has risen significantly in recent decades and nearly half a billion people worldwide are currently living with the condition. Obesity rates have also doubled since 1980 with over 13% of adults now classified as obese. Furthermore, around 10 million Americans have been diagnosed with thyroid disorders. These metabolic conditions burden healthcare systems and reduce productivity. Increased research into novel and more effective metabolism drugs could help more patients manage their conditions, boost health outcomes, and generate significant sales potential over the long term. Effective new treatments for metabolic diseases represent a lucrative growth avenue for leading drug manufacturers. Porter's Analysis Threat of new entrants: Low as high capital requirement and need for approvals favors large players. Bargaining power of buyers: Moderate as buyers can opt for substitutes if prices increase. Bargaining power of suppliers: Low due to availability of substitute raw materials. Threat of new substitutes: High as new alternative treatments can disrupt market. Competitive rivalry: Intense due to presence of many global and regional players. SWOT Analysis Strengths: Strong pipeline and focus on precision medicine. Availability of generic alternatives increases affordability. Weaknesses: Long regulatory approval timelines and high failure rates during clinical trials. Risk of drug resistance limits efficacy of existing drugs. Opportunities: Rising prevalence of metabolic disorders globally driven by lifestyle changes presents commercial opportunities. Scope for combination therapies targeting multiple issues. Threats: Stringent regulations and quality standards increase compliance costs challenging small players. Patent cliffs of blockbuster drugs enable competition. Key Takeaways The Global Metabolism Drugs Market Growth is expected to witness high growth the forecast period driven by increasing cases of obesity, diabetes and related disorders worldwide due to sedentary lifestyles and unhealthy diets. The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030. The market in North America currently dominates due to advanced healthcare infrastructure and high adoption of new therapies. However, Asia Pacific is expected emerge as the fastest growing region supported by large patient population, growing medical tourism industry and increasing healthcare spending in developing countries. Key players operating in the metabolism drugs market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd€TMS Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. These players are focusing on new product launches, collaborations and geographic expansion to consolidate their market position. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/metabolism-drugs-market-share-size-and-growth-share-trends-analysis-demand-forecast/
0 Comments
Melatonin is a hormone synthesized and released by the pineal gland in humans and other vertebrates. It regulates sleep-wake cycles and helps improve sleep and manage jet lag, shift work disorder, and insomnia. The increasing global prevalence of sleep disorders owing to a busy lifestyle and digital addiction has boosted the demand for melatonin supplements. These supplements help improve sleep duration and quality.
The global Melatonin Market is estimated to be valued at US$ 576.85 Mn in 2023 and is expected to exhibit a CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity for improving sleep quality is expected to boost the melatonin market growth significantly over the forecast period. Sleep quality refers to how well-rested one feels after sleeping and getting quality sleep is essential for overall well-being, mood, cognition and physical health. With increasing stress levels, irregular sleep schedules and digital addiction among people, sleep quality has deteriorated considerably across the world. This has augmented the demand for sleep supplements like melatonin that can enhance sleep architecture and promote deep sleep, resulting in better quality sleep. Melatonin supplements are effective in reducing sleep latency, increasing total sleep time and improving overall sleep experience. The wide-ranging benefits of melatonin in boosting sleep quality makes it an effective solution for treating lifestyle-induced sleep disorders, thereby presenting lucrative prospects for market players. Porter’s Analysis Threat of new entrants: The melatonin market is moderately difficult to enter due to required regulatory approvals and established distribution channels. However, the market is growing which can encourage new players. Bargaining power of buyers: Individual consumers have high bargaining power due to availability of substitutes. However, large pharmacies and retailers have low bargaining power due to the need to keep key brands in stock. Bargaining power of suppliers: Major players source active ingredients from few suppliers globally increasing their bargaining power. Suppliers also invest in R&D to develop improved formulations. Threat of new substitutes: New drugs for sleep disorders pose threat but melatonin is preferred being natural and over-the-counter. Other natural supplements also compete. Competitive rivalry: The market is consolidated with top players competing through new product innovation, mergers and acquisition. SWOT Analysis Strength: Natural formulation. Wide range of delivery forms. Growing consumer awareness on benefits. Weakness: Short shelf life. Need regular intake for effects. Absence of FDA approval for some uses. Opportunity: Untapped markets in developing countries. New areas of application research. Threats: Entry of private labels. Regulations on health claims. Key Takeaways The Global Melatonin Market Growth is expected to witness high over the forecast period. Asia Pacific region is expected to witness fastest growth supported by rising healthcare expenditure, quick adoption of technology and increased focus of key players. Regional analysis: North America currently dominates the global market owing to high consumer awareness levels and expenditure on alternative medicine therapies. However, Asia Pacific is projected to grow at the fastest pace with major opportunities in China and India driven by increasing disposable incomes and expanding modern retail outlets. Key players: Key players operating in the melatonin market are Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/melatonin-market-share-size-and-growth-share-trends-analysis-demand-forecast/ Medical sensors play a crucial role in healthcare monitoring as they are used to detect diseases, track physical activities, and monitor overall health and fitness. Various types of medical sensors such as biosensors, temperature sensors, image sensors, motion sensors, pressure sensors are used in patient monitoring, diagnostics, therapeutics and drug delivery. Biosensors are widely used in testing and diagnosing of various diseases and health conditions. Medical sensors help in remote patient monitoring by facilitating the transmission of acquired physiological data from patients to healthcare providers. This improves patient outcome as their conditions can be monitored in real-time outside of the clinic as well.
The global Medical Sensors market is estimated to be valued at US$ 22620.05 Mn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity The increasing demand for remote patient monitoring presents a huge opportunity for medical sensors market. Remote patient monitoring utilizes sensors and digital technologies to monitor patients outside of conventional clinical settings. It allows continuous collection of vital health data such as blood pressure, blood sugar, heart rate, oxygen saturation and temperature from patients. This helps in early detection of any deterioration and provides timely interventions. Many countries are implementing remote patient monitoring programs to reduce healthcare costs and improve patient outcomes. For instance, in the US, the Medicare program has expanded coverage for remote patient monitoring to manage chronic conditions. The growing geriatric population prone to chronic diseases will further drive the adoption of remote patient monitoring using medical sensors. This presents an immense opportunity for medical sensors manufacturers to develop advanced and miniaturized sensors for remote healthcare applications. Porter's Analysis Threat of new entrants: The medical sensors market requires high initial investments for R&D and innovation. Regulatory approvals also pose a barrier for new players. Bargaining power of buyers: Individual consumers have low bargaining power whereas large hospitals and diagnostic centers have moderate bargaining power due to the availability of alternatives and price sensitivity. Bargaining power of suppliers: The presence of various established sensor manufacturers globally makes it easy for buyers to switch to alternatives. This gives buyers a favorable position over suppliers. Threat of new substitutes: There is a gradual emergence of new sensor technologies like printed sensors or implantable sensors. However, their commercial viability remains limited. Competitive rivalry: The medical sensors market is becoming increasingly competitive with major players differentiating through innovation, quality, and customer service. SWOT Analysis Strengths: Medical sensors offer non-invasive monitoring and better patient outcomes. Technological advancements have increased sensor precision and miniaturization. Weaknesses: High costs and lack of portability restrain widespread adoption. Regulatory compliance involves lengthy approval cycles. Sensor reliability and data accuracy also present concerns. Opportunities: Growth areas include IoT-enabled remote patient monitoring, disposable sensor patches, and wearables. Emerging nations provide significant market potential. Threats: Stringent regulations on medical devices act as a barrier. Data privacy and cybersecurity threats challenge growth. Reimbursement policies affect demand. Key Takeaways The Global Medical Sensors Market Growth is expected to witness high driven by the increasing preventive healthcare spending and rising elderly population worldwide. The global medical sensors market is estimated to be valued at US$ 22620.05 Mn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030. North America dominates currently due to the presence of major players, frequent product innovations, and growing healthcare expenditure in the US and Canada. Asia Pacific is poised to grow at the fastest pace during the forecast period attributed to increasing disposable income, growing medical tourism, rising government funding for healthcare infrastructure development, and presence of low-cost device manufacturers in countries like China and India. Key players: Key players operating in the medical sensors market are Cargill, Incorporated, Archer Daniels Midland Company (ADM), Skretting (a part of Nutreco), Aller Aqua Group, BioMar Group, Ridley Corporation Limited, Purina Animal Nutrition (a subsidiary of Land O'Lakes), Nutriad International NV (acquired by ADM in 2018), BENEO GmbH, Dibaq Aquaculture. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/medical-sensors-market-share-size-and-growth-share-trends-analysis-demand-forecast/ The in-vitro meat market, also known as cultured meat or clean meat, involves growing animal muscle tissue in laboratory conditions without harvesting livestock. This approach to producing meat helps address the various issues associated with traditional industrial livestock farming such as environmental pollution, animal welfare, public health concerns, and greenhouse gas emissions. In-vitro or cultured meat is produced directly from animal cells through cellular agriculture and tissue engineering techniques. Some key advantages of cultured meat include reduced environmental footprint, no added hormones or antibiotics, prevention of diseases, and addressing concerns of animal welfare activists.
The global in-vitro meat market is estimated to be valued at US$ 2.15 Bn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The expansion of plant-based meat options presents a major market opportunity for the in-vitro meat market. Beyond Meat and Impossible Foods have witnessed immense success with their plant-based burger patties that mimic the taste and texture of meat. However, plant-based meats are still not able to effectively replicate the molecular structure and complete nutritional composition of animal meat. In-vitro cultured meat has the potential to match or surpass the quality attributes of conventional meat thereby positioning itself as a viable alternative to both animal meat and plant-based meat substitutes. As consumer interest in sustainable food options rises, the cultured meat market is well-positioned for strong growth by offering environment-friendly meat production without sacrificing on quality. Porter's Analysis Threat of new entrants: The threat of new entrants in the meat substitute market is moderate due to the requirement of large capital investments to construct production facilities and establish supply chains. Bargaining power of buyers: The bargaining power of buyers in the meat substitute market is high due to the availability of substitutes. Bargaining power of suppliers: Suppliers have moderate power due to availability of alternative raw materials and supplier concentration in the market. Threat of new substitutes: The threat of substitutes is moderate as there are several substitutes available for meat such as tofu, tempeh, eggs, dairy, etc. Competitive rivalry: The competitive rivalry in the meat substitute market is high due to the presence of several key players. SWOT Analysis Strengths: Meat substitutes offer high protein content, healthier and more sustainable alternatives to animal meat. Growing vegan and flexitarian population is increasing the demand. Weaknesses: High price of meat substitutes compared to conventional meat limits their adoption. Lack of texture and taste resembles meat is still a concern. Opportunities: Increasing health concerns regarding red meat and meat products is prompting consumers to shift to plant-based meat substitutes. New product launches catering to regional taste preferences present opportunities. Threats: Intense competition from other food categories and substitutes like eggs, dairy limits market scope. Consumer perception of meat substitutes as processed foods is a challenge. Key Takeaways The Global Meat Substitute Market Growth is expected to witness high over the forecast period of 2023 to 2030. The Market Size for 2023 is US$ 2.15 Bn. Regional analysis indicates that North America dominates currently due to growing vegan trends. However, Asia Pacific is expected to emerge as the fastest growing market due to increasing health awareness. Key players operating in the Meat Substitute Market are I-Minerals Inc., Quarzwerke GmbH, Eczacibasi Esan, Micronized Group, Imerys Minerals, Sibelco Nordic, The Quartz Corp., Adolf Gottfried Tonwerke GmbH, LB MINERALS, and Sun Minerals. These players are focusing on new product launches catering to regional tastes and preferences to further expand their market shares. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/meat-substitute-market-share-size-and-growth-share-trends-analysis-demand-forecast/ Industrial robotics include robotic arms, robotic grippers, and robotic tools that are used in various industrial automation processes such as material handling, welding, painting, assembly, packaging and product inspection among others. Industrial robots reduce the dependence on human workforce, improve production efficiency and consistently provide high-quality output to meet the global demand of commercial products and goods. Industrial robotics enable mass production in a cost-effective manner and minimizes wastage of raw materials. Robots have advanced sensors and controls that allow them to perform complex tasks with precision and consistency resulting in reduced production cycle time and less rework.
The global industrial robotics Market is estimated to be valued at US$ 60.91 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Cost Reduction in Assembly Line Automation Industrial robots provide significant cost savings to manufacturers by automating manual and repetitive assembly line tasks. Robots can work tirelessly in production lines without needing breaks and are not prone to errors caused by human fatigue. This leads to higher production volume, improved quality and reduced costs. Automating manual processes using robots eliminates costs associated with human labor such as wages, benefits, injuries and absenteeism. Robotic arms and tools can work 24/7 and complete tasks faster than humans, resulting in optimized utilization of facility space and resources. Assembly automation with robots minimizes rejects and reworks, significantly cutting down on material wastage. Overall, industrial robotics enable mass customization at lower unit costs by streamlining assembly operations. This presents a major market opportunity for industrial robotics manufacturers to automate manual assembly lines across industries and help customers reduce production costs. Porter’s Analysis Threat of new entrants: The industrial robotics market requires significant capital investments for R&D, production facilities, skilled workforce etc. Established players enjoy economies of scale. These factors make the threat of new entrants moderate. Bargaining power of buyers: The bargaining power of buyers is moderate as the industrial robotics technology is still nascent with limited alternatives. However, large factories have higher bargaining power. Bargaining power of suppliers: Key components like actuators, gears etc. are highly specialized with few global suppliers. This gives them moderate bargaining power over manufacturers. Threat of new substitutes: While additive manufacturing and other future technologies offer substitutions, they are yet to match the capabilities of industrial robotics. Substitution threat is low at present. Competitive rivalry: The industrial robotics market is highly consolidated with major global players. Intense competition keeps pricing pressure and forces players to invest in new technologies. SWOT Analysis Strengths: Growing automation demand from factories, cost savings compared to human labor, ability to perform repetitive & dangerous tasks accurately. Weaknesses: High initial installation costs, need for specialized engineering skills, limited flexibility for small batch production. Opportunities: Scope for collaborative robots, machine learning integration, remote monitoring & maintenance, expansion in SMEs and new applications. Threats: Trade barriers affecting global supply chains, economic slowdowns reducing factory investments, slow consumer adoption of robotic applications. Key Takeaways The Global Industrial Robotics Market Growth is expected to witness high at a CAGR of 4.8% during the forecast period of 2023 to 2030. Rapid factory automation driven by rising labor costs and the need for 24/7 operations will propel demand. Asia Pacific dominates currently due to massive electronics and automobile manufacturing in China, Japan, South Korea. Countries like China, Japan and South Korea are investing heavily in advanced robotics R&D and witness highest installation rates. Europe and North America are other major regional markets driven by strong automotive, food & beverage sectors. China alone accounts for over 30% of installations worldwide attributed to the massive manufacturing sector. Japan and South Korea also have a well-established robotics industry. Key players operating in the industrial robotics market are Asahi Glass Co. Ltd. (AGC), Corning Incorporated, SCHOTT AG, Incom Inc., Hamamatsu Photonics K.K., Nippon Electric Glass Co., Ltd. (NEG), II-VI Incorporated, Hamamatsu Corporation, Saint-Gobain S.A., Asahi Kasei Corporation, Leoni AG, TDK Corporation, Mitsubishi Chemical Corporation, Furukawa Electric Co., Ltd., GS Plastic Optics. These players are focusing on developing innovative collaborative robots catering to SMEs and new application areas like logistics, healthcare, and more. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/industrial-robotics-market-share-size-and-growth-share-trends-analysis-demand-forecast/ The Poultry Keeping Machinery Market is estimated to be valued at US$ 5563.33 Mn in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview: Poultry keeping machinery consists of hatcheries, feeding and watering equipment, egg processing equipment, waste management equipment, vaccination equipment, and handling and transport equipment. These machinery play a vital role in mass production and maintaining animal welfare standards in poultry farms. Growing consumption of poultry meat and eggs is boosting the demand for advanced poultry keeping machinery. Market key trends: The adoption of advanced technologies enabled automation and innovation in poultry keeping machinery is one of the key trends witnessed in the market. Several manufacturers are designing machinery integrated with Internet of Things (IoT), cloud computing, and automation to minimize human labor and monitor performance remotely. Automatic feeding systems, climate control systems, and vaccination machines are equipped with sensors and operated digitally. This is increasing productivity, traceability, and food safety in poultry farms. With the prevalence of concepts like precision livestock farming, implementation of technologies such as precision feeding is estimated to rise considerably over the forecast period. Porter’s Analysis Threat of new entrants: Low barriers for start-ups to enter the poultry keeping machinery market. However, established players have strong brand recognition and economies of scale. Bargaining power of buyers: Moderate as buyers can choose from various machinery brands. However, switching costs are high after initial investment. Bargaining power of suppliers: Moderate as machinery components are available from multiple suppliers globally. However, suppliers still have bargaining power over differentiated and proprietary technologies. Threat of new substitutes: Low as poultry keeping requires specialized machinery. No cost-effective alternatives exist for tasks like incubation, hatching, brooding and rearing of poultry. Competitive rivalry: High as major players compete on product quality, technology, pricing and service. SWOT Analysis Strength: Product innovation, advanced automation and energy efficient designs. Strong distribution network and after-sales support. Weakness: High R&D and marketing costs. Dependence on economic cycles in poultry industry. Opportunity: Growth in organized poultry farms and contract breeding. Adoption of data analytics and IoT in poultry operations. Threats: Strict biosecurity and safety regulations. Trade barriers and fluctuating raw material prices. Key Takeaways The Global Poultry Keeping Machinery Market Growth is expected to witness high, exhibiting CAGR of 3.4% over the forecast period, due to increasing mechanization in poultry farms. The market size for 2023 is estimated to be US$ 5563.33 Mn. Regional analysis: Asia Pacific dominates the global market with over 35% share due to large poultry production in China and India. Southeast Asia is expected to grow the fastest during the forecast period due to rapidly expanding organized sector and contract breeding in countries like Vietnam and Indonesia. Key players: Key players operating in the poultry keeping machinery market are Jansen Poultry Equipment, Petersime NV, Vencomatic Group, Big Dutchman International GmbH, Valco Companies, Inc., TEXHA PA LLC, Hartmann Lebensmitteltechnik Anlagenbau GmbH, and HAMEX-GROUP. They provide integrated solutions and focus on enhancing productivity through digitalization and automation. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/poultry-keeping-machinery-market-size-and-share-analysis-growth-trends-and-forecasts/ Portable ultrasound bladder scanners are compact medical devices used non-invasively to measure bladder volume and post-void residual urine remaining in the bladder. These scanners provide real-time imaging of the bladder and allow hospitals and clinics to efficiently monitor bladder volume and emptying. With advantages like portability, ease of use and safety, portable bladder scanners help improve workflow and patient experience in various clinical settings.
The global Portable Ultrasound Bladder Scanner Market is estimated to be valued at US$ 142.2 Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: One of the major market opportunities for portable ultrasound bladder scanners lies in improving patient experience in hospitals and clinics. Bladder scanners allow non-invasive, painless and quick assessment of bladder volume without the need for catheterization. This enhances comfort for patients especially in case of frequent monitoring needs. The portability and ease of use of these scanners also help streamline clinical workflows and reduce wait times. As patient satisfaction becomes a priority in healthcare, bladder scanners facilitate improved experience during visits to hospitals and clinics. Their ability to efficiently monitor bladder health in a manner which feels less intrusive to patients presents significant opportunity for market players in this domain. Porter's Analysis Threat of new entrants: Low cost of production machinery and growing demand present low barriers to entry. However, strong foothold of established brands and need for strong R&D deters new players. Bargaining power of buyers: Large customer base of hospitals and diagnostic centers gives buyers negotiating power to demand value added services and competitive pricing. Bargaining power of suppliers: Presence of numerous component manufacturers limits power of individual suppliers. However, integrating latest innovations is important. Threat of new substitutes: Other image-guided diagnostic techniques can substitute portable bladder scanners. However, portables offer convenience without radiation exposure. Competitive rivalry: Strong competition exists between global giants investing in R&D and local Asian manufacturers offering cost-effective products. SWOT Analysis Strength: Non-invasive nature and portability enables use at point-of-care. Growing geriatric population prone to urological issues increases demand. Weakness: High cost of advanced devices limits widespread adoption. Interpretation requires trained personnel in some cases. Opportunity: Emerging markets offer scope for penetration with affordable models. Tele-ultrasound can facilitate remote diagnosis. Threats: Reimbursement policies Economic slowdown can reduce healthcare budgets. Key Takeaways The Global Portable Ultrasound Bladder Scanner Market Growth is expected to witness high growth. The market size for 2023 is US$ 142.2 Mn and forecast period is from 2023 to 2030 with a CAGR of 6.3%. Regional analysis: North America dominates due to rapid technological adoption and availability of reimbursements. Asia Pacific is fastest growing region on back of unmet needs, improving access and rising medical tourism. China and India are major emerging markets. Key players operating in the portable ultrasound bladder scanner market are C. R. Bard, Inc. (Becton, Dickinson and Company), dBMEDx Inc., Healcerion Co., Ltd. , Verathon Inc., SRS Medical Systems Inc., Laborie Medical Technologies Inc., Lilium Otsuka Co. Ltd, Echo Son SA, Signostics Inc., Sonostar Technologies Co., Limited, Caresono Technology Co., Ltd., EchoNous, Roper Technologies, Inc., canon medical systems corporation , Koninklijke Philips N.V. , Siemens Healthcare GmbH, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ,alpinion medical systems co., Samsung healthcare and GE Healthcare Inc. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/portable-ultrasound-bladder-scanner-market-share-size-and-growth-share-trends-analysis-demand-forecast/ Polymer stabilizers are additives used to preserve the technical and aesthetic properties of polymers throughout their service lifetime. The most common polymers that require stabilizers are plastics like PVC, PET and polyurethane. Stabilizers protect polymers from degradation caused by heat, light and environmental stress factors like oxidation. They help extend the durability of polymers used in a variety applications like construction materials, packaging films and automotive parts.
The global Polymer Stabilizers Market is estimated to be valued at US$ 8.91 Bn in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity of enhanced service lifetime of various polymers through the use of stabilizers is expected to drive high growth of the polymer stabilizers market. Stabilizers play a crucial role in preserving properties of polymers by protecting them from degradation over time. This allows polymers to maintain their physical structure, appearance and performance for longer durations. The extended service life lowers the total cost of ownership for polymers used in various industries. Stabilizer manufacturers are developing solutions customized for specific polymer types and end-use requirements to maximize longevity. This growing need for polymers with longer operational lifespans will likely increase the demand for polymer stabilizers over the forecast period. Porter’s Analysis Threat of new entrants: The polymer stabilizers market requires huge investments for research and development activities. Also, key players have established brand names and distribution networks. These factors make it difficult for new players to enter the market. Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitute products. However, buyers prefer branded products for quality and consistency of product. Bargaining power of suppliers: A large number of raw material suppliers are present globally. This gives buyers option to negotiate with multiple suppliers thereby reducing suppliers bargaining power. Threat of new substitutes: Substitutes like thermal stabilizers are available but polymer stabilizers have wider applications giving less threat from substitutes. Competitive rivalry: The market has presence of many international players leading to high competition. Players differentiate based on product quality, technical support and services. SWOT Analysis Strength: Wide applications in industries like packaging, automotive and building & construction. Demand is backed by growth in end use industries. Weakness: Production is raw material intensive leading to volatility in prices. Stringent regulations regarding use of polymer stabilizers. Opportunity: Growth in emerging economies will provide new areas for expansion. Development of bio-based and eco-friendly polymer stabilizers. Threats: Impact of economic slowdowns on price of polymer stabilizers. Competition from substitute products. Key Takeaways The Global Polymer Stabilizers Market Growth is expected to witness high owing to increasing demand from construction and automotive industries globally. Regionally, Asia Pacific dominates the market and is expected to maintain its position during the forecast period. Growth in the region is driven by presence of emerging economies like China and India with huge population and rising construction activities. Asia Pacific region accounts for around 40% of global polymer stabilizers demand led by China, India and other Southeast Asian countries. Rapid industrialization and infrastructure growth is driving the polymer stabilizers consumption in the region. China dominates the Asia Pacific market with presence of huge polymer processing industry. Key players operating in the polymer stabilizers market are Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., Tempus Labs, Inc. These players are focused on new product launches, partnerships and expansions for business growth. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/polymer-stabilizers-market-share-size-and-growth-share-trends-analysis-demand-forecast/ Plasma protease C1-inhibitor treatment is a plasma-derived therapeutic used for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder characterized by episodes of severe swelling. Plasma protease C1-inhibitor treatment offers advantages such as reduced severity and frequency of HAE attacks.
The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: High unmet medical needs present a major market opportunity. Currently available treatment options suffer from certain limitations such as requirement of frequent dosing or intravenous administration. This leaves behind a sizable unmet need for easily administrable therapies with improved efficacy. Development of novel oral drugs or long acting therapies can help address this unmet need more effectively. This in turn is expected to boost the overall market growth during the forecast period. Porter's Analysis Threat of new entrants: The plasma protease C1-inhibitor treatment market requires huge R&D investment and regulatory approvals which makes it difficult for new players to enter. Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment options are limited and life saving. Bargaining power of suppliers: A few biotech companies dominate the supply chain resulting in higher bargaining power. Threat of new substitutes: Currently there are no effective substitutes available limiting threat from substitutes. Competitive rivalry: Major players compete on proprietary technologies and expanding indications resulting in high competitive rivalry. SWOT Analysis Strength: Established production facilities and strong R&D capabilities of major players. Demand is expected to rise with increasing prevalence of hereditary angioedema. Weakness: High treatment cost limiting accessibility. Requirement of patient monitoring and recurrent administrations. Opportunity: Scope for development of subcutaneous and extended half-life products. Approvals in new geographic regions. Threats: Price control regulations and strict biosimilar approval pathways. Supply chain disruptions and recalls. Key Takeaways The Global Plasma Protease C1-Inhibitor Treatment Market Growth is expected to witness high during the forecast period. The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030. North America dominates currently due to rapid adoption and high healthcare spending. Regional markets in Asia Pacific and Latin America are expected to grow at a higher pace due to rising awareness, diagnosis and economic growth. Key players operating in the plasma protease C1-inhibitor treatment market are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring dominates with leading intravenous products. Takeda and Ionis are developing subcutaneous options. Pharming and KalVista are exploring extended half-life versions to overcome limitations of frequent dosing. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/plasma-protease-c1-inhibitor-treatment-market-share-size-and-growth-share-trends-analysis-demand-forecast/ |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |